Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,938 total articles
Murphy USA (MUSA) is a trade to consider on the expectation that fuel margins will stay elevated into H2 2026. The stock trades with a mid-teens P/E, strong free cash flow and an attractive EV/EBITDA multiple for a high-return retailer. I lay out an entry, stop and target for a long-term tactical trade and the key risks that could derail the thesis…
Fortinet combines a durable, ASIC-accelerated security platform with strong cash generation and accelerating revenue, but it trades at a premium multiple and elevated EV/sales that limit upside. The trade: a measured mid-term long with defined risk controls while monitoring growth and margin trajectory.
MercadoLibre is trading well below its 52-week high after a correction that amplified concerns tied to Brazil. The company reported blowout revenue growth and strong fintech traction; balance sheet and cash flow strength support a tactical long. Entry at $1947.26, stop at $1800, target $2500 over a long term (180 trading days) horizon.
Rocket Lab (RKLB) is priced for perfection on Neutron, but the business can still deliver a credible quarter driven by launches, backlog and defense contracts. The trade: go long near $67 with a $57 stop and a $95 target over the next 45 trading days, while watching Neutron schedule and margins closely.
ACI Worldwide is a profitable, cash-generative payments software company trading at a reasonable multiple with a clear path to higher recurring revenue and margins. Recent M&A, product wins in open banking and a large addressable market for real-time payments support a long trade. Entry at $53.00, stop at $48.00, target $65.00 over a long-term (180…
Kazia Therapeutics ($KZIA) is a small-cap biotech where upcoming clinical readouts and regulatory interactions could validate paxalisib as a best-in-class PI3K/mTOR inhibitor for brain and selected solid tumors. At a market cap of roughly $167M and a current price near $14.60, the stock is priced for outcome sensitivity. This trade targets asymmetr…
Teradyne is transitioning from a cyclical semiconductor-test supplier to a structural beneficiary of AI-driven semiconductor and robotics demand. Strong Q2 results, widening guidance, and improving free cash flow create a favorable risk/reward around $370. Trade plan: enter at $370.00, stop $330.00, target $460.00 (primary) over a 180-trading-day h…
Vontier’s recent top-line stagnation masks a healthier earnings and free-cash-flow profile. With FCF of $384.8M, EPS near $2.57 and an EV/EBITDA of 8.9, the balance between operational leverage and a still-manageable balance sheet makes a tactical long where upside to analyst targets looks reachable and downside is containable with a tight stop.
TotalEnergies is trading at $87.26 with a market cap near $198B, a P/E of 10.6 and a 4.4% dividend yield. The company is benefiting from elevated commodity realizations and operational progress on projects like GranMorgu, while integrating AI and digital partners to shave costs. We favor a mid-term long (45 trading days) entry designed to capture d…
Nvidia's 08/26/2026 quarter blew past expectations: $96.2B revenue (106% YoY), $29.2B adjusted net income, and management guiding to $108B for the next quarter. The market has briefly priced in deceleration despite record profits; that disconnect creates an asymmetric risk/reward for a disciplined long with a $223 entry, $200 stop and $300 target o…
Cogent Biosciences (COGT) has lined up three regulatory filings for bezuclastinib across Non-Advanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM) and GIST. FDA acceptance and robust SUMMIT data support a tactical long into the late-2026 decision window. Entry at $37.00, stop at $30.00, target $60.00, long term (180 trad…
Joby has industry-leading progress on FAA certification and deep pockets from partners, yet the stock remains priced for perfection (price-to-sales ~61x) and management's recent capital actions have increased dilution risk. Trade the squeeze between regulatory headlines and financing overhang: short with a tight stop and a mid-term horizon to captu…
Quanta Services (PWR) has been hit by a rapid derating from its 2026 highs. The selloff creates a favorable risk-reward: the company sports a near-record backlog, healthy free cash flow and shareholder-friendly actions, while valuation and sentiment have pulled back enough to justify a tactical long. This trade idea lays out an entry at $620.00, a …
Synopsys is the core EDA and IP provider quietly baked into the chip design flows that power next-generation AI chips. With a $78.5B market cap, $2.75B in free cash flow and partnership momentum around agentic engineering toolkits, the stock looks like a tactical buy on strength in design automation demand. This trade plan buys the stock near curre…
GSK ($51.44) combines a resilient commercial franchise, meaningful vaccine exposure and a mid-teens P/E with a 3.4% yield. Technicals are neutral-to-bullish and the company sits squarely in expanding vaccine markets (influenza, HPV). I recommend a long trade sized for a diversified portfolio: entry $51.40, primary target $62.00, stop loss $48.00, h…
Siemens Energy has pushed through a painful restructuring cycle. With improved execution across Gas, Grid, and Siemens Gamesa, the stock looks primed for a tactical long. This trade targets a recovery driven by backlog conversion, better margin trajectory and falling working capital pressure.
Zymeworks is shifting its identity from a development-stage biotech to a hybrid commercial/royalty-driven platform. With licensed assets in the mix, a $929M acquisition of Theravance (bringing YUPELRI® with $266.6M in 2025 U.S. sales), fresh commercial upside and a deeper R&D bench, the company has optionality that could justify a higher multiple. …
Okta's fundamentals and guidance from the May quarter keep the buy case intact: 11% revenue growth in Q1 to $765M, $271M of FCF in the quarter and a FY27 revenue guide near $3.2B. However, the stock now trades at a premium (EV/sales ~7.7, trailing P/E ~95) and recent outperformance narrows the margin for execution mistakes. This trade proposes a di…
AT&T trades at $25.89 with a 4.5% yield, a single-digit P/E and an EV/EBITDA of ~6.5. The balance sheet still carries leverage, but free cash flow of ~$13.3B and a 36-45% payout framework make the dividend resilient. This trade targets a reversion toward the 52-week high and a modest re-rating as subscriber stability, cash flow and buybacks normali…
Bloom Energy is trading like a growth juggernaut after a string of blowout quarters and a $20 billion backlog. Fundamentals justify the story, but the valuation is demanding. This is a structured swing trade: respect the premium, limit position size, and use a tight stop to capture a potential re-rating while protecting against profit-taking.
Waste Management is a high-quality compounder: strong ROE (28.7%), predictable free cash flow ($3.57B), and essential services that keep revenue resilient in downturns. At $221, the stock is priced richly (P/E ~31, P/B ~8.9, EV/EBITDA ~14.3). This trade idea recommends waiting for a pullback to $205 to initiate a position, using a $195 stop, and ta…
Celestica's role as an assembler of complex AI server racks and its strong Q1 print and raised guidance position it to benefit disproportionately if the so-called 'Jalapeño' AI chip ramps hit hyperscalers. Valuation is elevated but not prohibitive given $19B revenue guidance and robust profitability metrics. We upgrade to Buy and outline a mid-term…
Urban Outfitters is delivering above-consensus results, expanding margins and converting subscription strength into healthier cash flow. The shares trade at a reasonable multiple against steady fundamentals and improving operating metrics. We upgrade to a buy and propose a clear swing trade: entry $83.00, target $95.00, stop $74.00 over a 45 tradin…
Super Micro (SMCI) sits at the intersection of surging AI-server demand and capital strain. Order momentum, improving gross margins and strong quarterly earnings justify a buy, but a $6.85B trailing free-cash-flow hole, ongoing equity raises, and regulatory/governance overhangs make position sizing and stops essential.
Disney is trading at a reasonable multiple today despite strong cash flow and a resurgent experiences business. If theatrical multiplex attendance and studio monetization recover — and streaming margins stabilize — Disney's current $189B market cap and $230B enterprise value look conservative. This trade idea lays out an actionable buy with entry, …
